News

June 2013

Election of IASLC officers and members of the Board of Directors are ongoing and the deadline is July 16, 2013.

The World Conference on Lung Cancer in Sydney is coming closer - October 27-30, 2013. A record high number, more than 2,300, of abstracts have been received for the conference and will now be evaluated by the Program Committee. Notification to the abstract authors is scheduled to July 26, 2013. Please, take advantage of the early registration with the deadline of August 2, 2013.

DENVER – The International Association for the Study of Lung Cancer (IASLC) will host the 15th World Conference on Lung Cancer (WCLC) Oct. 27-30, 2013 in Sydney, Australia. The World Conference on Lung Cancer (WCLC) is the world's largest meeting dedicated to lung cancer and other thoracic malignancies.

May 2013

IASLC Election for officers and members of the Board of Directors is approaching. Please see instructions below. The election process will start June 11 and run through July 16, 2013.

The World Conference on Lung Cancer in Sydney is coming closer - October 27-30, 2013. Please note that the deadline for abstract is June 21, 2013 and we hope as many members as possible will submit abstracts. Please refer to www.iaslc.org for more information. The IASLC would like to draw your attention to the special travel awards offered to the patient’s advocates.

NORTHFIELD, ILL.— The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number one cancer killer in the United States and abroad. Now, for the first time after a decade of biomarker testing in lung cancer, a uniform approach for testing for the EGFR mutation and ALK rearrangement along with the availability of targeted therapies offer lung cancer patients the chance for improved quality of life and more time with their loved ones.

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have developed an evidence-based
guideline, "Molecular Testing Guideline for the Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors," which establishes recommendations for EGFR and ALK testing, helping to guide targeted therapies. The guideline was released on April 3, 2013, in Archives of Pathology & Laboratory Medicine (APLM), Journal of Thoracic Oncology, and The Journal of Molecular Diagnostics.

DENVER – The International Association for the Study of Lung Cancer (IASLC) invites patient advocates to apply for the organization's Advocacy Travel Awards. The IASLC will offer travel awards to a limited number of patient advocates to participate in the World Conference on Lung Cancer (WCLC) Oct. 27-30, 2013 in Sydney, Australia. Awardees receive free conference registration, up to four nights' accommodations, a free IASLC Membership and a cash award for 1,000 AUD.

April 2013

The World Conference on Lung Cancer in Sydney is coming closer, October 27-30, 2013. A very exciting program has been established by the program committee and particularly the two Conference Presidents, Drs. Michael Boyer and Kwun Fong. Please note that the deadline for abstract is June 21, 2013 and we hope as many members as possible will submit abstracts. The IASLC would like to draw your attention to the special travel awards offered to the patient’s advocates.

A significant step towards implementation of personalized medicine for lung cancer patients is the recent publication of the CAP/IASLC/AMP Guidelines for Molecular Testing. The IASLC is proud to be a part of this development, which should improve patient care and secure the many patients with lung cancer the most optimal therapy based on standardized and validated molecular tests. The IASLC is currently putting considerable effort into implementing these guidelines in clinical practice.

Pages